Biotech News
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results
ir.anaptysbio.com2026-05-06 14:57 EST
Spin-off of biopharma operations into a public company to be called “First Tracks Biotherapeutics” on track for Q2 2026, potentially as early as late-April Phase 1b enrollment ongoing in celiac disease and trial cohort initiated in eosinophilic esophagitis for ANB033, a CD122 antagonist GSK